Biomarin Pharmaceutical stock hits 52-week low at $52.93
NegativeFinancial Markets

Biomarin Pharmaceutical's stock has reached a 52-week low, closing at $52.93, which raises concerns among investors about the company's current performance and future prospects. This decline could impact investor confidence and the company's ability to raise capital for ongoing research and development, making it a significant event in the biotech sector.
— Curated by the World Pulse Now AI Editorial System